Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Medtronic plc Director's Dealing 2017

Mar 6, 2017

29841_dirs_2017-03-06_7b5d0561-2539-4b30-a83a-8ea2b93a9023.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Medtronic plc (MDT)
CIK: 0001613103
Period of Report: 2017-03-02

Reporting Person: HOGAN RANDALL J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-03-02 Ordinary Shares M 15109 $27.38 Acquired 32458 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-02 Stock Option (Right to Buy) $27.38 M 15109 Disposed 2017-07-02 Ordinary Shares (15109) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 286 Indirect

Footnotes

F1: This balance increased by 35 shares due to exempt transactions such as dividend reinvestment.

F2: In the Merger, Covidien options outstanding as of closing were converted into options to buy shares of New Medtronic. This option to purchase 15,109 New Medtronic ordinary shares for $27.38 per share was received in the Merger and represents the conversion of 10,521 Covidien ordinary shares for $39.32 per share, which were fully vested at the time of the Merger. The conversion ratio and exercise price was calculated according to the terms of the Transaction Agreement, which does not allow for options on fractional shares of New Medtronic. Other than as to the number of underlying shares and the exercise price, this New Medtronic stock option has the same terms and conditions as the original Covidien stock option.